Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre. Oral Presentation: Title: Targeting the hepat